Scinai Immunotherapeutics SCNI Q4 2023 Earnings NarrowerThanExpected Loss Amid Operational Adjustments FNLC Q1 2026 Earnings Solid EPS Performance Amidst Quiet Market Reaction RxSight Q1 2026 Earnings EPS Misses Estimates by 32 as Operational Costs Weigh VIV Q1 2026 Earnings EPS Misses Estimates Stock Sheds 172 Telomir Pharmaceuticals TELO Q4 2025 Earnings WiderthanExpected Loss Amid Ongoing Development MiNK Therapeutics Q1 2026 Earnings Narrowed Loss Exceeds Expectations Amid Clinical Progress